The restatements reveal severe internal control failures across multiple quarters. Unrestricted cash has nearly depleted (down to $163K by Sept 2025 from $13.9M at Dec 2024). The company announced a planned Nasdaq up-listing and engaged E.F. Hutton, suggesting near-term equity or debt capital raise is imminent. Monitor for Form S-1 filing, terms of any offering, and auditor attestation on remediation progress. The AML litigation ($1.02M claim) and FIAU penalty ($420K) add contingent liability overhang.
Price Chart
Executive Summary
FDCTech filed two amended 10-Qs (Q2 and Q3 2025) to restate previously issued financial statements following the discovery of material errors. The restatements correct eight major items including: reclassifying $8M in subscription receivables to contra-equity, adding 500K unrecorded common shares from 2021, separately presenting $7.1M in client restricted cash, fixing noncontrolling interest allocation, correcting lease accounting under ASC 842, reclassifying cost of sales between segments, and correcting the AIL acquisition from ASC 805 to common-control accounting. Net loss for the six months ending June 30, 2025 improved by $207K to $111K due to restatement adjustments. Management identified multiple material weaknesses in internal controls and has begun remediation. The company faces ongoing litigation including a $1.02M claim from former AML shareholders and a €420K FIAU penalty appeal. These filings signal deep, multi-period accounting problems that fundamentally undermine the reliability of previously reported financials.
Key Facts
- Total assets as of June 30, 2025 restated from $47.5M to $31.7M, a $15.9M reduction
- Subscription receivable of $8.2M reclassified from current assets to contra-equity per ASC 505-10-45-2
- 500,000 common shares issued October 2021 were not previously recorded in share register
- Client funds of $7.1M (APL and AML) reclassified from Cash to Restricted cash with corresponding liability
- Net loss for 6 months ended June 30, 2025 improved from $319K to $111K on $208K other income correction
- Total stockholders' equity at June 30, 2025 restated from $16.2M to $8.2M (including NCI of $42K)
- Cash balance collapsed from $13.9M (Dec 2024) to $163K (Sep 2025), excluding restricted client funds
- Multiple material weaknesses identified in internal controls including subscription receivables, stock tracking, restricted cash, NCI allocation, and common-control identification
- Simultaneous restatement of multiple periods: FY 2024, FY 2025, and all 2025 quarters through Q1 2026
- Company engaged E.F. Hutton for potential Nasdaq up-listing; filed $2M sellers note for Alchemy International acquisition
Financial Impact
Balance sheet restatement reduced total assets by $15.9M, equity by $8.0M (excluding NCI), with cash going from reported $26.2M to restated $2.3M (June 2025). Net loss improved $208K for H1 2025. By September 30, 2025, unrestricted cash was only $163K. Restatements span multi-year periods.
Risk Factors
- Going concern risk: unrestricted cash declined to $163K at Sep 2025 from $13.9M at Dec 2024
- SEC enforcement risk from multi-period restatement and internal control material weaknesses
- Litigation risk: $1.02M AML shareholder claim with trial set for Nov 2026; $420K FIAU penalty appeal
- Dilution risk from planned equity offering for Nasdaq up-listing
- Reliance on related-party transactions (Kundnani-controlled entities) for acquisitions and financing
- Loss of auditor confidence after multiple auditor changes (4 firms since 2021)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-Q/A Filing (FDCT) — Batch item 1 | 0001493152-26-027768 |
| Exhibit: ex31-1.htm | 0001493152-26-027770 |
| Exhibit: ex31-2.htm | 0001493152-26-027768 |
| Exhibit: ex32-2.htm | 0001493152-26-027768 |
| Exhibit: ex32-1.htm | 0001493152-26-027768 |
| Document: 0001493152-26-027768-index-headers.html | 0001493152-26-027768 |
| Document: 0001493152-26-027768-index.html | 0001493152-26-027768 |
| Document: 0001493152-26-027768.txt | 0001493152-26-027768 |
| 10-Q/A Filing (FDCT) — Batch item 9 | 0001493152-26-027770 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $3.99 | awaiting T+60 | — | $4.37 (+9.52%) |
Oct 2, 2026 25d ago | EFFECT | $2.01 | awaiting T+60 | — | $4.37 (+117.41%) |
Sep 24, 2026 4w ago | S-1/A | $2.85 | awaiting T+60 | — | $4.37 (+53.33%) |
Sep 22, 2026 5w ago | 8-K | $2.10 | awaiting T+60 | — | $4.37 (+108.10%) |
Sep 15, 2026 5w ago | S-1 | $0.9900 | awaiting T+60 | — | $4.37 (+341.41%) |
Sep 10, 2026 6w ago | 8-K | $0.9999 | awaiting T+60 | — | $4.37 (+337.04%) |
Aug 26, 2026 8w ago | 8-K | $1.25 | awaiting T+60 | — | $4.37 (−249.60%) |
Jun 23, 2026 17w ago | 8-K | $3.11 $0.9900 | ▲ +68.17% | ▲ +71.46% | $4.37 (−40.51%) |
Jun 23, 2026 17w ago | 10-K/A | $3.11 $0.9900 | ▲ +68.17% | ▲ +71.46% | $4.37 (−40.51%) |
Jun 8, 2026 20w ago | 8-K | $6.00 $1.00 | ▲ +83.33% | ▲ +87.41% | $4.37 (+27.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers